Key points are not available for this paper at this time.
The purpose of the study was to compare the effectiveness of PARP inhibitor maintenance therapy (mPARPi) in real-world practice by biomarker status BRCA1/2 alterations (BRCAalt) and a homologous recombination deficiency signature (HRDsig) in advanced ovarian cancer.
Richardson et al. (Tue,) studied this question.